The ITA notifies wrestler Iman Mohammadi of an apparent anti-doping rule violation
The International Testing Agency (ITA), which leads an independent anti-doping program for United World Wrestling (UWW), confirms that it has notified Iman Mohammadi from Iran of an adverse analytical finding (AAF) for GW1516.
The ITA reports that a sample collected on 22 October 2025 during the U23 World Championships from Mr Iman Mohammadi, a wrestler from Iran, has returned an AAF¹ for two metabolites of the prohibited substance GW1516.
GW1516 is listed under section S4.4 “Metabolic Modulators” of the 2025 WADA Prohibited List. It is a drug that activates pathways involved in fat metabolism in the body and that improves endurance performance. GW1516 is a non-specified substance prohibited at all times (in- and out-of-competition).
The athlete has been informed of the case and has the right to request the analysis of the B-sample.
If the B-sample analysis is requested and confirms the A-sample result, the case will proceed as a confirmed anti-doping rule violation. If the B-sample analysis is not requested, the case will also proceed as a confirmed violation. The athlete will have the opportunity to provide his explanations for the result.
Further, in accordance with the World Anti-Doping Code and Article 7.4.1 of the UWW Anti-Doping Rules, a mandatory provisional suspension has been imposed on the athlete. He has the right to challenge the provisional suspension and request its lifting.
Pursuant to the UWW’s delegation of its anti-doping program to the ITA, the prosecution of the case is being handled entirely by the ITA. Given that the case is underway, there will be no further comments made.
The original press release can be found here: https://ita.sport/news/the-ita-notifies-wrestler-iman-mohammadi-of-an-apparent-anti-doping-rule-violation/
